Protocol Ledger

NCT07792681 · Phase II/III · RECRUITING

Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

Interventional Phase II/III clinical trial protocol NCT07792681 sponsored by Brise Pharmaceuticals Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-30 Enrollment: 2,079 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07792681
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,079 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07792681
Protocol FieldVerified Registry Value
NCT IdentifierNCT07792681
Consolidated Lead SponsorBrise Pharmaceuticals Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment2,079 participants (ESTIMATED)
Registered Start Date2026-09-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI